全文获取类型
收费全文 | 309723篇 |
免费 | 59888篇 |
国内免费 | 14155篇 |
专业分类
耳鼻咽喉 | 3469篇 |
儿科学 | 7240篇 |
妇产科学 | 4227篇 |
基础医学 | 47102篇 |
口腔科学 | 9094篇 |
临床医学 | 41593篇 |
内科学 | 56058篇 |
皮肤病学 | 9544篇 |
神经病学 | 24334篇 |
特种医学 | 10226篇 |
外国民族医学 | 101篇 |
外科学 | 36415篇 |
综合类 | 37305篇 |
现状与发展 | 44篇 |
一般理论 | 53篇 |
预防医学 | 19621篇 |
眼科学 | 7257篇 |
药学 | 31297篇 |
170篇 | |
中国医学 | 13289篇 |
肿瘤学 | 25327篇 |
出版年
2024年 | 821篇 |
2023年 | 3541篇 |
2022年 | 9112篇 |
2021年 | 12815篇 |
2020年 | 13016篇 |
2019年 | 17451篇 |
2018年 | 17410篇 |
2017年 | 17800篇 |
2016年 | 18136篇 |
2015年 | 21301篇 |
2014年 | 23849篇 |
2013年 | 23476篇 |
2012年 | 21114篇 |
2011年 | 22449篇 |
2010年 | 20723篇 |
2009年 | 14736篇 |
2008年 | 14373篇 |
2007年 | 13519篇 |
2006年 | 12841篇 |
2005年 | 12246篇 |
2004年 | 9114篇 |
2003年 | 8580篇 |
2002年 | 7602篇 |
2001年 | 6479篇 |
2000年 | 6113篇 |
1999年 | 5433篇 |
1998年 | 3187篇 |
1997年 | 3212篇 |
1996年 | 2525篇 |
1995年 | 2318篇 |
1994年 | 2039篇 |
1993年 | 1385篇 |
1992年 | 1942篇 |
1991年 | 1669篇 |
1990年 | 1457篇 |
1989年 | 1310篇 |
1988年 | 1227篇 |
1987年 | 1060篇 |
1986年 | 935篇 |
1985年 | 748篇 |
1984年 | 573篇 |
1983年 | 458篇 |
1982年 | 353篇 |
1981年 | 325篇 |
1980年 | 277篇 |
1979年 | 313篇 |
1978年 | 248篇 |
1977年 | 271篇 |
1976年 | 236篇 |
1974年 | 201篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
23.
24.
25.
高压氧综合治疗持续植物状态30例疗效分析 总被引:14,自引:0,他引:14
目的评估高压氧综合治疗持续植物状态的疗效和探讨最佳治疗方案。方法回顾性分析了1999年—2005年应用高压氧治疗的30例持续植物状态病例,主要分析了原发病因、高压氧治疗次数以及高压氧治疗时机与疗效的关系。结果脑外伤组显效率和好转率明显高于非脑外伤组(P<0.05),开始治疗时间≤30d组及31~60d组好转率明显高于≥61d组(P<0.05)。结论高压氧综合治疗对脑外伤所致持续植物状态患者60d以内开始行高压氧治疗的患者疗效较好。 相似文献
26.
We report clinical, neuroradiologic features, and neuropathologic findings of a 76‐year‐old man with coexistent Pick’s disease and progressive supranuclear palsy. The patient presented with loss of recent memory, abnormal behavior and change in personality at the age of 60. The symptoms were progressive. Three years later, repetitive or compulsive behavior became prominent. About 9 years after onset, he had difficulty moving and became bed‐ridden because of a fracture of his left leg. His condition gradually deteriorated and he developed mutism and became vegetative. The patient died from pneumonia 16 years after the onset of symptoms. Serial MRI scans showed progressive cortex atrophy, especially in the bilateral frontal and temporal lobes. Macroscopic inspection showed severe atrophy of the whole brain, including cerebrum, brainstem and cerebellum. Microscopic observations showed extensive superficial spongiosis and severe neuronal loss with gliosis in the second and third cortical layers in the frontal, temporal and parietal cortex. There were Pick cells and argyrophilic Pick bodies, which were tau‐ and ubiquitin‐positive in neurons of layers II–III of the above‐mentioned cortex. Numerous argyrophilic Pick bodies were observed in the hippocampus, especially in the dentate fascia. In addition, moderate to severe loss of neurons was found with gliosis and a lot of Gallyas/tau‐positive globus neurofibrillary tangles in the caudate nucleus, globus pallidus, thalamus, substantia nigra, locus coeruleus and dentate nucleus. Numerous thorned‐astrocytes and coiled bodies but no‐tuft shaped astrocytes were noted in the basal ganglion, brainstem and cerebellar white matter. In conclusion, these histopathological features were compatible with classical Pick’s disease and coexistence with progressive supranuclear palsy without tuft‐shaped astrocytes. 相似文献
27.
28.
C. M. Crceles J. M. Serrano P. Marín E. Escudero E. Fernndez‐Varn 《Transboundary and Emerging Diseases》2006,53(6):300-304
The pharmacokinetics (PK) of moxifloxacin in healthy white New Zealand rabbits was studied following intravenous (IV) and subcutaneous (SC) administration routes as well as a SC long‐acting poloxamer 407 gel formulation (SC‐P407). Moxifloxacin concentrations were determined by high‐performance liquid chromatography assay with fluorescence detection. Mean half‐life for IV, SC and SC‐P407 routes was 2.15, 5.41 and 11.09 h. Clearance value after IV dosing was 0.78 l/kg/h. After SC administration, the mean absolute bioavailability was 117% and the Cmax was 1.61 ± 0.49 mg/l. After SC‐P407 administration, the bioavailability was 44% and the Cmax 1.83 was ±0.62 mg/l. No adverse effects were observed in any of the rabbits following IV, SC and SC‐P407 administration of moxifloxacin. Minimal inhibitory concentrations of moxifloxacin against different strains of Staphylococcus aureus from different european countries were used to compute the main pharmacodynamic (PD) surrogate markers of efficacy. The high tolerability of this SC‐P407 formulation and the favourable PK behaviour such as the long half‐life, acceptable bioavailability and excellent PK–PD ratios achieved indicate that it is likely to be effective in rabbits. 相似文献
29.
A new semi-empirical formula for the evaluation of (n,(3)He) reaction cross-sections at the energy of 14.6 and 20 MeV is presented. Formula was derived using the analytical expression for the evaluation of the (3)He spectrum within the frame of pre-equilibrium exciton model. The systematics obtained is compared with the empirical formula for the (n,(3)He) reaction cross-section. 相似文献
30.